Eli Lilly | LLY - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -4.58B 1.35B 2026-09
Abbott USD 51.03B 83M 2026-09
ALKERMES USD 1.86B 56.17M 2026-09
Amgen USD 14.35B 2.66B 2026-09
AstraZeneca USD 51.73B 1.43B 2026-09
Baxter International USD 6.5B 296M 2026-09
Biogen USD 19.04B 194.3M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Coherus Biosciences USD 60.84M 17.78M 2026-06
Drreddys Laboratories INR 389.37B 8.91B 2026-09
Eli Lilly USD 40.27B 6.39B 2026-09
Gilead Sciences USD 13.04B 1.3B 2026-09
GlaxoSmithKline GBP 18.75B 1.11B 2026-09
Glaxosmithkline GBP 18.36B 940M 2026-09
J&J USD 81.53B 3.44B 2026-09
Medtronic USD 50.23B 160M 2026-06
Merck USD 44.89B 2.96B 2026-09
Neurocrine Biosciences USD 3.88B 185.1M 2026-09
Novartis USD 37.23B 4.72B 2026-09
Novartis USD 37.56B 1.36B 2026-09
Novo Nordisk DKK 221.28B 18.21B 2026-06
Perrigo USD 2.44B 75.4M 2026-09
Pfizer USD 89B 3.81B 2026-09
Phibro Animal Health USD 417.67M 32.19M 2026-09
Prestige Brands USD 1.94B 27.95M 2026-09
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 72.88B 3.31B 2026-09
Sanofi EUR 69.57B 3.58B 2026-06
United Therapeutics USD 6.28B 124.3M 2026-09
Zoetis USD 3.3B 155M 2026-09